Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
By most measures, Pfizer looks like the ideal target for some activist treatment.
The US pharmaceutical company enjoyed outsized gains during the pandemic thanks to its Covid-19 vaccine developed with BioNTech. Sales topped $100bn in 2022.
But as demand for the shot waned, so did sales. Attempts to develop an obesity drug have been a flop. Pfizer’s shares have fallen…
Read the full article here